Patients with acute unilateral vestibulopathy (AUVP)
Conditions
Brief summary
Disease-related quality of life assessed by the change of the DHI value between inclusion and day 14 post study inclusion.
Detailed description
Disease-related quality of life assessed by change of the DHI value between inclusion and day 7, 45, 60, 90 and 180 post study inclusion, Health-related quality of life (assessed by EQ-5D-5L) at day 7, 14, 45, 60, 90, and 180 post study inclusion., Slow-phase velocity (SPV) of spontaneous nystagmus at day 7, 45, and 180 days after study inclusion, Total postural sway (with eyes closed) at day 7, 45, and 180 post study inclusion, Rate of conversion to secondary functional dizziness at day 180 post study inclusion
Interventions
DRUGL-Thyroxin beta 200 μg Tabletten
Sponsors
Klinikum der Universitaet Muenchen AöR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-related quality of life assessed by the change of the DHI value between inclusion and day 14 post study inclusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-related quality of life assessed by change of the DHI value between inclusion and day 7, 45, 60, 90 and 180 post study inclusion, Health-related quality of life (assessed by EQ-5D-5L) at day 7, 14, 45, 60, 90, and 180 post study inclusion., Slow-phase velocity (SPV) of spontaneous nystagmus at day 7, 45, and 180 days after study inclusion, Total postural sway (with eyes closed) at day 7, 45, and 180 post study inclusion, Rate of conversion to secondary functional dizziness at day 180 post study inclusion | — |
Outcome results
None listed